PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
36.29%
Revenue growth above 1.5x CRON.TO's 13.16%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
57.21%
Gross profit growth under 50% of CRON.TO's 223.20%. Michael Burry would be concerned about a severe competitive disadvantage.
-181.24%
Negative EBIT growth while CRON.TO is at 125.11%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-181.24%
Negative operating income growth while CRON.TO is at 122.09%. Joel Greenblatt would press for urgent turnaround measures.
-57.90%
Negative net income growth while CRON.TO stands at 167.61%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-53.60%
Negative EPS growth while CRON.TO is at 159.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-60.74%
Negative diluted EPS growth while CRON.TO is at 150.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.09%
Share reduction more than 1.5x CRON.TO's 11.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.10%
Diluted share reduction more than 1.5x CRON.TO's 34.68%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
210.71%
OCF growth above 1.5x CRON.TO's 50.97%. David Dodd would confirm a clear edge in underlying cash generation.
-9.01%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.57%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
4994.38%
OCF/share CAGR of 4994.38% while CRON.TO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
1997.53%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
733.01%
10Y net income/share CAGR of 733.01% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
838.92%
Net income/share CAGR of 838.92% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
2455.14%
3Y net income/share CAGR above 1.5x CRON.TO's 124.33%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1295.21%
Equity/share CAGR of 1295.21% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
2660.69%
Equity/share CAGR of 2660.69% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
6638.11%
3Y equity/share CAGR above 1.5x CRON.TO's 429.40%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52.39%
Firm’s AR is declining while CRON.TO shows 12.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
43.08%
Inventory growth well above CRON.TO's 39.85%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
30.23%
Asset growth well under 50% of CRON.TO's 64.85%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
30.94%
50-75% of CRON.TO's 52.08%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-3.01%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-13.16%
Our R&D shrinks while CRON.TO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
10.77%
SG&A declining or stable vs. CRON.TO's 42.19%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.